Xpeng Rally Met Our 46 Target, Pullback in Progress
Xpeng has rallied nicely from our buy in level at 23 and met our ideal target at 46, a pullback is now in the cards back to the old pivot support...
361 Views
China ADRs - Now the Message Is Loud and Getting Clearer
In our previous note we spoke about the recent crackdown on the three US listed firms. Since then more news has been coming in along the same theme...
455 Views
Daojia Pre-IPO - Can’t Pinpoint the True Growth
Daojia Limited (DL), one of the largest one-stop home services platforms in China, aims to raise US$300m in its US IPO, which now may or may not...
239 Views
Xpeng Motors HK Trading - More Hot with Instis that Retail
Xpeng Motors (XPEV US) raised around US$2bn via a listing in Hong Kong. In this note, we will talk about the trading dynamics and the updates since...
292 Views
ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
423 Views